Clinical Trials Logo

Shingles clinical trials

View clinical trials related to Shingles.

Filter by:

NCT ID: NCT06238726 Recruiting - Behavior, Health Clinical Trials

Nudging Patients to Increase Shingles Vaccination

Start date: March 25, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to test whether messages encouraging patients to ask about a Shingrix vaccine at an upcoming appointment will increase Shingrix vaccination rates. The study will also test which of several message versions is most effective.

NCT ID: NCT05871541 Active, not recruiting - Infectious Disease Clinical Trials

A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

JCXH-105
Start date: May 26, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to assess the safety and immunogenicity of a self-replicating (sr) RNA-based vaccine, JCXH-105, in the prevention of Shingles (Herpes Zoster) Participant will be randomized to receive either JCXH-105 or Shingrix.

NCT ID: NCT05703607 Recruiting - Shingles Clinical Trials

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Start date: January 25, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune system's reaction) of the study vaccine called Varicella Zoster Virus modRNA (VZV modRNA). We are seeking for healthy participants who are between 50 and 69 years of age. This study will be conducted in 2 substudies: Substudy A (Phase 1) and Substudy B (Phase 2). Substudy A: This substudy is the Phase 1 portion of the study. In this substudy, participants will receive 1 of 3 VZV modRNA vaccine candidates (different construct, different dose levels and different formulation [frozen or freeze dry powder]) or the approved shingles vaccine intramuscularly. Participants will be assigned in 1 of 14 groups in the study. Vaccination will be given either as a 2-dose series using one of two dosing schedules (either 2-months apart or 6-months apart), or (in one of the groups), as a single VZV modRNA vaccine at the first vaccination visit and saline at the second vaccination visit. Participants will take part in this study for 8 to 12 months depending on the group they are assigned to. Some group(s) will continue into persistence-of-immunity (overtime assessment of effect of vaccine) portion of the study. Those participants assigned to these selected groups will be involved in the study for up to 5 years. Substudy B: This substudy is the Phase 2 portion of the study. In this part of the study, participants will receive either VZV modRNA vaccine at selected dose level/schedule/formulation or approved shingles vaccine. This selection will be determined from Substudy A. Participants will be involved in this study for up to 5 years.

NCT ID: NCT05596526 Recruiting - Shingles Clinical Trials

Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients

MSHINGVAX
Start date: December 1, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to provide evidence as to whether RZV is immunogenic with an acceptable safety profile in Multiple Sclerosis patients on anti-CD20 treatment.

NCT ID: NCT05554068 Recruiting - Shingles Clinical Trials

Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Start date: March 7, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.

NCT ID: NCT05304351 Active, not recruiting - Herpes Zoster Clinical Trials

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

Start date: February 2, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and immunogenicity of CRV-101, an investigational vaccine compared to Shingrix for the prevention of herpes zoster in adults aged 50 years and older

NCT ID: NCT05245838 Completed - Herpes Zoster Clinical Trials

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

Start date: January 10, 2022
Phase: Phase 1
Study type: Interventional

This is a randomized, active-controlled, dose-escalation multi-center study of 2 doses (Day 1 and Week 8) of an investigational herpes zoster (HZ) vaccine (Z-1018), combining herpes zoster antigen- (gE) with a Toll-like receptor 9 (TLR9) agonist adjuvant (CpG 1018) with and without alum in approximately 150 healthy volunteers 50 to 69 years of age (inclusive).

NCT ID: NCT04540081 Completed - Obesity Clinical Trials

Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer

CLOVER
Start date: October 5, 2020
Phase: N/A
Study type: Interventional

The purpose of CLOVER is to utilize Epic Healthy Planet to increase adherence to United States Preventive Services Task Force (USPSTF) and Centers for Disease Control and Prevention (CDC) recommendations in adults age 50 and older.

NCT ID: NCT04099706 Completed - Chronic Pain Clinical Trials

Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT

Start date: September 19, 2019
Phase: N/A
Study type: Interventional

This randomized clinical trial investigates the possible beneficial effect of autologous fat grafting on postherpetic neuralgia.

NCT ID: NCT04047979 Completed - Shingles Clinical Trials

Systems Biology of Zoster Vaccine

Start date: November 14, 2019
Phase: Phase 2
Study type: Interventional

The purpose of the study is to better understand how the immune system responds to the new herpes zoster (shingles) vaccine (Shingrix®). The study will be looking at certain markers in the blood after vaccination with Shingrix®.